Proximal in Medical Technology

Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results

... with no increased risk." The PAS-Port proximal Anastomosis System Advantage The innovative ... product is used in more than 20 percent of all proximal anastomoses performed using a vein bypass graft ... the United States and Europe and its PAS-Port(R) proximal Anastomosis System is marketed in the United ...

Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery

... CRDC ) today announced that the PAS-Port(R) proximal Anastomosis System achieved its primary endpoint ... efficacy of our PAS-Port system." The PAS-Port proximal Anastomosis System Advantage The innovative ... product is used in more than 20 percent of all proximal anastomoses performed using a vein bypass graft ...

Cardica to Host Investor Briefing on 'Revolutionizing Revascularization'

... prospective, randomized pivotal clinical trial of its PAS-Port(R) proximal Anastomosis System will be presented at the 2008 Annual Scientific Meeting ... Systems are marketed in Europe and the United States. The PAS-Port(R) proximal Anastomosis System is marketed in Europe and Japan, and Cardica has ...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

... joints were stratified 2:1 Metacarpal Phalangeal Joint, or MP joint, to proximal Intra-Phalangeal, or PIP joint. The primary endpoint was met with 64% (130 ... or MP joint, which is the joint closest to the palm of the hand and the proximal Intra-Phalangeal Joint, or the PIP joint, which is the middle joint in the ...

DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

... asthma. orBec(R) is formulated for oral administration as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract. In addition to issued patents ...

Applying Clinical Findings to the Practice of Medicine

... of care is surgery." Dr. Hurst and his team injected Clostridial collagenase to the joint and reduced contractures in metacarpophalangeal and proximal interphalangeal joints within zero degrees to five degrees of normal extension after the last injection. An additional study in humans with ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

... associated with liver toxicity. Decreases in bone mineral density (BMD) have been seen with tenofovir DF. Cases of osteomalacia (associated with proximal renal tubulopathy) have been reported in association with the use of tenofovir DF. Use ATRIPLA with caution in patients with a history of ...

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

... associated with liver toxicity. Decreases in bone mineral density (BMD) have been seen with tenofovir DF. Cases of osteomalacia (associated with proximal renal tubulopathy) have been reported in association with the use of tenofovir DF. Use ATRIPLA with caution in patients with a history of ...

Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg

... self-expanding stent versus balloon angioplasty alone in treating peripheral arterial disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery. These arteries are the major circulatory channels for the upper leg and knee. "The RESILIENT Trial is a randomized, multi-center ...

European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)

... associated with liver toxicity. Decreases in bone mineral density (BMD) have been seen with tenofovir DF. Cases of osteomalacia (associated with proximal renal tubulopathy) have been reported in association with the use of tenofovir DF. Use ATRIPLA with caution in patients with a history of ...

Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

... associated with liver toxicity. Decreases in bone mineral density (BMD) have been seen with tenofovir DF. Cases of osteomalacia (associated with proximal renal tubulopathy) have been reported in association with the use of tenofovir DF. Use ATRIPLA with caution in patients with a history of ...

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

... treatment with XIAFLEX. The primary endpoint of the study is to determine if XIAFLEX can reduce the contracture angle in metacarpophalangeal (MP) or proximal interphalangeal (PIP) joints to within 0 to 5 degrees of normal. Upon completion of the double-blind trial in the U.S., all patients are eligible to ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

... 62% reduction of risk (p=0.01) for developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the secondary endpoint of ... (RRR 49%; p less than 0.001). Major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the main secondary efficacy ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

... (62%) reduction of risk (p=0.01) of developing major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death), the secondary endpoint of the ... patients receiving enoxaparin (RRR 49%; p Major VTE (the composite of proximal DVT, non-fatal PE and VTE-related death) - the main secondary efficacy ...

Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY

... secretion, indicating that the hormone acts as an enterogastrone -- a hormone released from the distal portion of the small intestine that inhibits proximal gastrointestinal events. Another important action of GLP-1 is to induce satiety. About PYY Peptide YY 3-36 is produced by the gut and is released ...

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes

... currently in Phase IIb development. About SGLT2 Inhibitors Glucose is normally filtered by the kidney, but nearly all of it is reabsorbed in the proximal tubule by SGLT2, which is located almost exclusively in the kidney. For patients with diabetes, retention of excess glucose by this pathway ...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

... the primary endpoint (2.8% vs. 4.9%; p=0.0011) was associated with a reduction in symptomatic VTE by 73% (0.3% vs. 1.1%; p=0.0044) and asymptomatic proximal DVT by 34% (2.5% vs. 3.7%; p=0.0319). No statistically significant differences were observed for symptomatic pulmonary embolism (PE) or fatal PE. ...

Appendicitis: Evolving Tools to Diagnose a Classic Disease

... lethal condition that affects 7% of individuals sometime in their lives. The condition occurs when the appendix, a blind pouch of intestine at the proximal colon, becomes obstructed by mucus, stool, or lymphatic tissue. Infection ensues, which can rapidly evolve to perforation and sepsis. The risk of ...